NCT05729620

Evaluation of STARgraft-3 for Hemodialysis

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 21 (estimated)
• Sponsor: Healionics Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a single site, prospective, single arm evaluation of the safety and effectiveness of the Healionics STARgraft-3 hemodialysis access graft. STARgraft devices have been demonstrated in preclinical and other studies to have improved resistance to the common failure modes of venous anastomosis stenosis and infection. This study is an extension from prior studies with STARgraft AV (NCT03916731) and STARgraft-2 (NCT04783779) investigational devices. A previous study also included control implants of commercially available standard ePTFE grafts approved for the same use. The study is enrolling patients with End Stage Renal Disease (ESRD) requiring hemodialysis via a prosthetic vascular graft. The study proposes to evaluate the performance of the investigational STARgraft-3 compared to the ePTFE controls in the prior study and to published results, over a period of 6 months, with extended results to 1 year. Estimated enrollment is 15 subjects in this study.

Conditions

• End Stage Renal Disease

Interventions

Type	Name	Description
DEVICE	Implant of STARgraft-3 shunt in the upper arm and subsequent use for hemodialysis access	After healing from the surgical procedure, the graft will be routinely cannulated for hemodialysis sessions. Periodic evaluations of blood flow by ultrasound imaging will be made over the study period. Established standards of care will be followed as needed to maintain dialysis function.

Timeline

• Start date: 2022-11-29
• Primary completion: 2024-02-01
• Completion: 2024-07-01
• First posted: 2023-02-15
• Last updated: 2024-02-01

Locations

1 site across 1 country: Paraguay

Regulatory

• FDA-regulated device study